Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR–tyrosine kinase inhibitors (EGFR–TKIs). However, the C797S mutation, which impairs the covalent binding between the cysteine residue at posi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature communications Jg. 8; H. 1; S. 14768
Hauptverfasser:	Uchibori, Ken, Inase, Naohiko, Araki, Mitsugu, Kamada, Mayumi, Sato, Shigeo, Okuno, Yasushi, Fujita, Naoya, Katayama, Ryohei
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Nature Publishing Group UK 13.03.2017 Nature Publishing Group Nature Portfolio
Schlagworte:	13/31 13/95 38/109 631/67/1059/2326 631/67/1612/1350 64/60 Acrylamides Aniline Compounds Animals Antibodies, Monoclonal - pharmacology Antineoplastic Agents - pharmacology Antineoplastic Combined Chemotherapy Protocols Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Cell Line, Tumor Cetuximab - chemistry Cetuximab - pharmacology Drug Resistance, Neoplasm ErbB Receptors - antagonists & inhibitors ErbB Receptors - chemistry ErbB Receptors - genetics ErbB Receptors - metabolism Gene Expression Humanities and Social Sciences Humans Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - mortality Lung Neoplasms - pathology Mice Mice, Nude Molecular Dynamics Simulation multidisciplinary Mutation Organophosphorus Compounds - chemistry Organophosphorus Compounds - pharmacology Panitumumab Piperazines - pharmacology Protein Kinase Inhibitors - pharmacology Pyrimidines - chemistry Pyrimidines - pharmacology Science Science (multidisciplinary) Survival Analysis Tumor Burden - drug effects Xenograft Model Antitumor Assays
ISSN:	2041-1723, 2041-1723
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!